(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer | ||||||
incorporation or organization) | Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
LIGAND PHARMACEUTICALS INCORPORATED | |||||
Date: October 18, 2023 | By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary |
Cover Page |
Oct. 18, 2023 |
---|---|
Cover [Abstract] | |
Entity Central Index Key | 0000886163 |
Amendment Flag | false |
Document Type | 8-K |
Document Period End Date | Oct. 18, 2023 |
Entity Registrant Name | LIGAND PHARMACEUTICALS INC |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-33093 |
Entity Tax Identification Number | 77-0160744 |
Entity Address, Address Line One | 3911 Sorrento Valley Boulevard, Suite 110 |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92121 |
City Area Code | 858 |
Local Phone Number | 550-7500 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | LGND |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
RHY_U=3_ 102P,$% @ 9TA25Y>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/: (7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU M1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$ MG53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7 D(GP&LK\,S4-AB.G8RF M2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&3K;V"%TH M?653#@%%G=W4Q7/4 6_*P>-HK(0* Y1OJA65UY**+2?=T>M,[Q\FCUI&Z]Q* MN??P2K8<
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end
L7[T0S6O)QPAT8=D7\"O'\H9A!7A>M6_6=JS)O['*
MT9NI KW0861/GG%GV^C.WU^>W'Z\>>1LTV7L ^_50J_%8P5M#=SDR[.,:XN-
M)Y."T9$)1 X>*J1'&:8_-%,FLYB'>C!E#VW\ /?.A,T=>@RL41_K\PC(:%T^
M -UDAH4. P[4 ,2JZZ[Q29,C#4!M'.X*UV
MA:J1]MH,*AT-O@=4A=^T]5-[W5QJ[[0/4?CY,*>S*?&I9#[76J/*U9-K$$):
M'"_5#UA ,/4=I_..3\WSV,3V! X4Z+JKK4[7?KE9DW!DO76,WTAPC;%:*:[N
M:3#)-090U5RS@6UY>ZX=973^,1'RX3_R<8J(GLFDX!#)4$(L> )4A&D88@]
M$3B8*6E6V;X886PB7%=J:Y2@A DT3M-J]B6170O9'O0,4\-V9\:B>&V)OD?=
M^M+CP"5K2T#;U6J;H:V0/\3SS8?NB(L)DH05$Z@'<:"*A2$_@)X?T2!T':1"
M:J;A9^ :"^@RL)!JB2T>>
M22/D&(7)UZWWHV/R!